UAE accelerates diagnostics push ahead of WHX 2027

The UAE is emerging as a regional test bed for advanced clinical diagnostics as investment in genomics, AI, lab networks and reimbursement reshapes care delivery. A new WHX report says that momentum will be on display at Labs Zone during WHX 2027 in Dubai.

Why it matters: - The UAE is building the infrastructure needed to move advanced diagnostics from pilot projects into routine care. - That shift could affect how hospitals, labs and payers across the Gulf adopt genomics, molecular testing and AI-enabled pathology. - The Middle East diagnostics market is estimated at US$5.4 billion in 2026, making the UAE increasingly important within a fast-growing sector.

What happened: - World Health Expo released a new report with Frost & Sullivan titled "From Infrastructure to Innovation: The GCC’s Growing Influence on Clinical Diagnostics." - The report says the global clinical diagnostics market will grow from US$115.7 billion in 2026 to US$152.1 billion by 2031, a 5.5% compound annual growth rate. - WHX also announced that Labs Zone at WHX 2027 will connect global diagnostics suppliers with buyers and decision-makers across the region. - WHX 2027 runs from 25-28 January 2027 at the Dubai Exhibition Centre, Expo City Dubai and Dubai World Trade Centre. - The event is expected to draw more than 90,000 attendees, 4,200 exhibitors and representatives from more than 195 countries. - WHX 2027 is part of World Healthcare Week, alongside WHX Tech and WHX Leaders.

The details: - The UAE is advancing genomics, laboratory infrastructure, AI-enabled diagnostics and reimbursement in parallel. - The report says that approach is creating a model for faster adoption and stronger clinical decision-making. - The Emirati Genome Programme is building population-level genomic datasets to support personalized healthcare and research. - Cleveland Clinic Abu Dhabi provides precision oncology services, next-generation sequencing, genetic counseling and hereditary cancer testing. - Since January 2025, genetic testing has been mandatory for Emiratis during premarital screening. - That screening covers 570 genes linked to more than 840 genetic conditions. - Frost & Sullivan projects the molecular diagnostics market will grow from US$26.9 billion in 2026 to US$36 billion by 2031. - The report cites oncology molecular profiling, companion diagnostics and infectious disease surveillance as key growth drivers. - Reimbursement across the GCC now covers oncology next-generation sequencing, non-invasive prenatal testing and decentralized molecular testing. - PureHealth’s PureLab, the UAE’s largest integrated laboratory network, completed 34 million tests in 2025. - That total was up 17% from 29 million tests in 2024. - Frost & Sullivan projects point-of-care testing will grow from US$19.1 billion in 2026 to US$26.2 billion by 2031, a 6.4% annual growth rate. - Rapid testing platforms are moving into urgent care, community settings and other sites outside the traditional laboratory. - The report says large hospital groups and integrated primary care networks are becoming more important buyers of diagnostics. - Connectivity, remote quality monitoring and laboratory information system integration are becoming baseline requirements in GCC tenders. - The Labs Zone conference program will cover molecular diagnostics, genomics, histopathology, clinical microbiology, AI and digital pathology. - The conference chairs will include leaders from M42’s National Reference Laboratory, PureLab, Dubai Health, SEHA Blood Bank Services, the Emirates Clinical Chemistry Society and Emirates Drug Establishment. - WHX said the Labs Zone is intended to place diagnostics companies in front of the hospital groups, distributors, procurement teams and clinicians who influence adoption.

Between the lines: - The report suggests the UAE’s advantage is not only technology spending, but coordination across regulation, reimbursement and clinical infrastructure. - That combination matters because diagnostics adoption often slows when systems cannot fund, integrate or operationalize new tools. - The emphasis on procurement standards and network buyers signals a more mature market, where interoperability and monitoring may matter as much as test performance. - The Labs Zone is positioned as a commercial meeting point for that shift, not just a conference venue.

What's next: - WHX 2027 will use the Labs Zone and its diagnostics conference track to showcase products, partnerships and clinical use cases. - The event will also serve as a venue for suppliers seeking access to Gulf buyers as reimbursement and laboratory networks continue to expand. - The full report is available as the WHX Global Clinical Diagnostics Report.